Cargando…
The p97/VCP segregase is essential for arsenic-induced degradation of PML and PML-RARA
Acute Promyelocytic Leukemia is caused by expression of the oncogenic Promyelocytic Leukemia (PML)–Retinoic Acid Receptor Alpha (RARA) fusion protein. Therapy with arsenic trioxide results in degradation of PML-RARA and PML and cures the disease. Modification of PML and PML-RARA with SUMO and ubiqui...
Autores principales: | Jaffray, Ellis G., Tatham, Michael H., Mojsa, Barbara, Liczmanska, Magda, Rojas-Fernandez, Alejandro, Yin, Yili, Ball, Graeme, Hay, Ronald T. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Rockefeller University Press
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10005898/ https://www.ncbi.nlm.nih.gov/pubmed/36880596 http://dx.doi.org/10.1083/jcb.202201027 |
Ejemplares similares
-
Expression and Function of PML-RARA in the Hematopoietic Progenitor Cells of Ctsg-PML-RARA Mice
por: Wartman, Lukas D., et al.
Publicado: (2012) -
PML-RARA mutations confer varying arsenic trioxide resistance
por: Bai, Dong-Mei, et al.
Publicado: (2016) -
PML isoforms in response to arsenic: high-resolution analysis of PML body structure and degradation
por: Hands, Katherine J., et al.
Publicado: (2014) -
Arsenic-Induced SUMO-Dependent Recruitment of RNF4 into PML Nuclear Bodies
por: Geoffroy, Marie-Claude, et al.
Publicado: (2010) -
The DNA Binding Property of PML/RARA but Not the Integrity of PML Nuclear Bodies Is Indispensable for Leukemic Transformation
por: Liu, Xi, et al.
Publicado: (2014)